NewLink Genetics Corp. (NLNK) reported that its first-quarter of 2013 net loss widened to $7.9 million or $0.33 per share from $4.8 million or $0.23 per share in the first quarter of 2012.
Total grant revenues for the first quarter 2013 were $302,000 compared with $471,000 for the first quarter 2012.
Research and development expense for the first quarter 2013 was $6.3 million compared with $3.8 million for the first quarter 2012. The $2.5 million increase was primarily due to increased manufacturing and clinical trial expense from the same period in 2012.
General and administrative expense for the first quarter 2013 was $2.0 million compared with $1.5 million for the first quarter 2012. This increase was primarily due to increases in personnel related expenses.
The company said it expects to end 2013 with about $40 million in cash, cash equivalents and marketable securities.
Analysts polled by Thomson Reuters expected the company to report a loss of $0.28 per share on revenues of $0.4 million for the quarter. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.